Perspective Therapeutics (CATX) Accumulated Depreciation (2011 - 2026)

Perspective Therapeutics has disclosed Accumulated Depreciation across 14 years of filings, most recently posting $7.3 million for Q1 2026.

• Accumulated Depreciation for Q1 2026 came in at $7.3 million, up 98.59% year-over-year; the trailing twelve-month figure through Mar 2026 was $7.3 million (up 98.59% YoY), and the FY2025 annual result was $6.2 million, up 109.59% from the prior year.
• Accumulated Depreciation came in at $7.3 million for Q1 2026 at Perspective Therapeutics, up from $6.2 million in the prior quarter.
• In the past five years, Accumulated Depreciation ranged from a high of $8.3 million in Q3 2023 to a low of $15000.0 in Q4 2022.
• The 5-year median for Accumulated Depreciation is $5.2 million (2025), against an average of $4.8 million.
• Across the five-year window, Accumulated Depreciation slumped 99.8% in 2022 and surged 4360.0% in 2023, its largest moves.
• Perspective Therapeutics' Accumulated Depreciation stood at $15000.0 in 2022, then soared by 4360.0% to $669000.0 in 2023, then soared by 342.45% to $3.0 million in 2024, then surged by 109.59% to $6.2 million in 2025, then increased by 18.12% to $7.3 million in 2026.
• The last three Accumulated Depreciation figures came in at $7.3 million (Q1 2026), $6.2 million (Q4 2025), and $5.2 million (Q3 2025), per Business Quant data.